1. Home
  2. |Insights
  3. |C5 - 23rd Annual Forum on Biotech & Pharmaceutical Patenting

C5 - 23rd Annual Forum on Biotech & Pharmaceutical Patenting

Event | 10.10.12 - 10.11.12, 12:00 AM UTC - 12:00 AM UTC

C5’s 23rd Forum on Biotech & Pharmaceuticals Patenting brings together experienced in-house counsel from both innovator and generic pharma and biotech companies and their expert legal advisors from various jurisdictions across the globe. Based on their personal experience, the expert panel will lead you through invaluable, practical, and in-depth sessions on:

  • The latest case law developments regarding SPCs and the impact on the industry
  • The patentability of diagnostic methods and the implications of the Prometheus case in the US
  • A comparison of the approaches in the EU member states on research exemptions in clinical trials
  • The use of patent litigation insurance cover to enable smaller life science developers to protect their IP
  • The latest strategies and priorities of the EPO
  • A comparison of the approaches to inventiveness in different member states in the EU
  • Procedural developments in Europe, including developments in evidence collection proceedings
  • Analysing the US Biosimilars Framework  and developments in the EU
  • An update on case law in key jurisdictions including the US, UK, Germany, France and Switzerland

Sean-Paul will be speaking during the session "Minimise the Risk of Your Patent Strategy Falling Foul of Anti-Competition Laws in the US and the EU in an Era of Heightened Regulatory Scrutiny."

Insights

Event | 02.20.25

Has the Buss Stopped? Recoupment Today

Has the Buss Stopped? Recoupment Today: In 1997, the California Supreme Court decided Buss v. Superior Court. In Buss, the court concluded that a liability insurer that defended a mixed action could seek reimbursement from the insured for the defense costs associated with the claims that were not even potentially covered. Since then, numerous courts have held that insurers are entitled to recoup their defense costs associated with uncovered claims or causes of action. On the other hand, a significant number of courts have rejected insurers’ right to recoupment, at least in the absence of a policy provision granting the insurer that right. Some commentators have even suggested that the current judicial trend might be away from permitting insurers to recoup their defense costs. Is that correct? Has the Buss stopped? This panel of coverage experts will analyze insurers’ claimed right to recoupment today, and offer their perspectives on what the law on recoupment should perhaps be and might be in the future.

View All Insights